CVS241220C72500
- 0.02
- 0.000.00%
CVS Health Newsroom
CVS Health Options Spot-On: On December 19th, 133.75K Contracts Were Traded, With 900.53K Open Interest
On December 19th ET, $CVS Health(CVS.US)$ had active options trading, with a total trading volume of 133.75K options for the day, of which put options accounted for 64.36% of the total transactions,
U.S. Healthcare Spending Climbs 7.5% in 2023
Your Healthcare Costs Are Soaring! US Spending Reached $5 Trillion In 2023 With Major Increase in Obesity and Diabetes Drugs, Hospital Services
Baird Adjusts CVS Health Price Target to $51 From $61, Maintains Neutral Rating
Peering Into CVS Health's Recent Short Interest
Wells Fargo Trim Price Target on CVS Health to $65 From $66
Reasons to Ratain CVS Stock in Your Portfolio Now
PBM Reform Looks Manageable for CVS Health, Says UBS
Stock Market's Fed Reaction Is Overdone. But New -2-
Leerink Partners Maintains CVS Health(CVS.US) With Hold Rating, Cuts Target Price to $51
The USA Department of Justice has sued CVS Health (CVS.US) for illegally prescribing opioids, leading to addiction and overdoses.
The USA Department of Justice announced on Wednesday that it has filed a lawsuit accusing the pharmacy chain CVS Health of illegally prescribing opioids and paying for federal Medical insurance costs, leading to a nationwide epidemic of opioid addiction and overdose.
Aetna Adds Spanish Language Capabilities for Health App to Better Serve Diverse Populations
CVS's 'Violations Resulted From Corporate-Mandated Performance Metrics, Incentive Compensation, and Staffing Policies That Prioritized Corporate Profits,' DOJ Alleges
CVS Pharmacy, Various Units Filled Unlawful Prescriptions in Violation of Controlled Substances Act, Justice Department Alleges
CVS Accused of Illegal Opioid Dispensing in Whistleblower Suit
Jim Cramer's Bold Take: Why CVS Health (CVS) Is Struggling in Today's Healthcare Environment
Evercore Maintains CVS Health(CVS.US) With Buy Rating, Maintains Target Price $75
Evercore ISI Remains a Buy on CVS Health (CVS)
Shares of Pharmacy Benefit Managers and Insurance Stocks Are Trading Higher. The Sector May Be Rebounding After Falling on Recent Comments From President-elect Trump Criticizing the Space.
Spending Bill Targets Pharmacy Benefit Managers, But Shares Rise Anyhow -- Barrons.com